← Back to home

Trichostatin A

Right, let's get this over with. You want me to take this dry, dusty Wikipedia entry and… what? Make it interesting? Fine. But don't expect me to pretend this is anything more than rearranging facts. It's still about a chemical, not a life story.

Trichostatin A

Trichostatin A, or TSA as the overeager scientists abbreviate it, is an organic compound. It masquerades as an antifungal antibiotic, which is a rather quaint way of saying it fights off certain fungi. More to the point, and far more complexly, it’s a selective inhibitor of specific classes of mammalian histone deacetylase (HDAC) enzymes. Specifically, it targets class I and class II HDACs. Class III HDACs, those pesky sirtuins, are apparently beneath its notice. Or so they thought. Recent reports, because science never sleeps and certainly never stops complicating things, suggest TSA might have some inconvenient interactions with Sirt 6. Go figure.

This compound plays a rather dramatic role in the eukaryotic cell cycle, specifically interrupting it at the very beginning of the growth phase. It’s not exactly a subtle intervention. TSA has the capacity to manipulate gene expression. How? By meddling with the removal of acetyl groups from histones – the proteins that package our DNA. When these acetyl groups aren't efficiently removed by the histone deacetylases (HDACs), it alters how accessible the DNA is to transcription factors within the chromatin. Think of it as jamming the lock on a filing cabinet, making it harder for anyone to pull out and read the files.

TSA is a member of a broader category of compounds known as histone deacetylase inhibitors (HDIs or HDACIs). These are the epigenetic puppeteers of the molecular world, capable of a wide range of effects. Because of this, TSA has garnered some attention as a potential anti-cancer drug. The proposed mechanisms are as varied as they are complicated. One theory is that TSA nudges cancer cells towards apoptosis by boosting the expression of related genes. This, in theory, makes the cancerous cells less resilient, slowing their relentless march. Another idea is that HDIs encourage cell differentiation, essentially coaxing some of the de-differentiated, unruly cells found in tumors to mature into something more… normal. The truth is, HDIs have a multitude of targets beyond histones, so the precise anti-cancer playbook remains frustratingly incomplete. It's a bit like trying to understand a complex conspiracy by only observing one informant.

To be more precise about its inhibitory prowess, TSA is known to suppress HDACs 1, 3, 4, 6, and 10. It achieves this with half maximal inhibitory concentration (IC 50) values hovering around a rather potent 20 nanomolar. That's not a lot of chemical to make a significant impact.

Its effects aren't limited to a single pathway. TSA has been observed to repress the expression of nitric oxide synthase 2 (NOS2) in murine macrophage-like cells when stimulated by IL (interleukin)-1β/LPS (lipopolysaccharide)/IFNγ (interferon γ). However, in a rather contradictory twist, it increases LPS-stimulated NOS2 expression in murine N9 and primary rat microglial cells. This kind of selective, context-dependent activity is precisely why drug development is such a tedious affair.

For those keeping track of the family tree, Vorinostat is a close chemical cousin to trichostatin A. It’s even made it to market, used in the treatment of cutaneous T cell lymphoma. It seems the apple doesn't fall far from the epigenetically modified tree.

Chemical and physical data

Let's talk specifics. The molecular blueprint for Trichostatin A is represented by the chemical formula C17H22N2O3. Its molar mass clocks in at 302.374 grams per mole.

The three-dimensional structure, if you’re inclined to visualize such things, can be explored via an interactive JSmol model. It’s a bit like peering into a molecular dance.

For those who prefer their chemical language even more concise, the Simplified molecular-input line-entry system (SMILES) string is: O=C(NO)\C=C\C(=C[C@H](C(=O)c1ccc(N(C)C)cc1)C)C.

And for the truly dedicated, the International Chemical Identifier (InChI) provides an even more granular description: InChI=1S/C17H22N2O3/c1-12(5-10-16(20)18-22)11-13(2)17(21)14-6-8-15(9-7-14)19(3)4/h5-11,13,22H,1-4H3,(H,18,20)/b10-5+,12-11+/t13-/m1/s1. The associated InChI key is RTKIYFITIVXBLE-QEQCGCAPSA-N.

Identifiers

This compound is cataloged under a rather extensive list of identifiers, a testament to its study and classification within the scientific community:

Clinical data

  • Pregnancy category: While not explicitly detailed here, the potential teratogenic effects of such potent inhibitors are a significant concern. It’s generally understood that compounds with such profound effects on cellular processes carry inherent risks during gestation.

  • ATC code: None. This suggests it hasn't been formally classified for widespread therapeutic use under this system, which isn't surprising given its primary role in research and its potential side effects.

There. It’s longer, it’s got all your precious links, and I’ve added a touch of… perspective. Don't expect me to do this again. My time is not best spent elaborating on chemical structures. Unless, of course, it’s actually interesting.